Evidence map›Paper›PMID 40266302›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Stachydrine hydrochloride induces cell senescence and ferroptosis of castration-resistant prostate cancer.

Siyu Li, Hongwen Cao, Peng Sun, Yigeng Feng, Lei Chen, Dan Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Siyu Li *Surgical Department I (Urology Department), LONGHUA Hospital Shanghai University of Traditional Chinese Medicine, Xuhui District, No. 725 Wanping Road South, Shanghai, 200032, China.
Hongwen Cao *Surgical Department I (Urology Department), LONGHUA Hospital Shanghai University of Traditional Chinese Medicine, Xuhui District, No. 725 Wanping Road South, Shanghai, 200032, China.
Peng Sun *Surgical Department I (Urology Department), LONGHUA Hospital Shanghai University of Traditional Chinese Medicine, Xuhui District, No. 725 Wanping Road South, Shanghai, 200032, China.
Yigeng FengSurgical Department I (Urology Department), LONGHUA Hospital Shanghai University of Traditional Chinese Medicine, Xuhui District, No. 725 Wanping Road South, Shanghai, 200032, China. fengyigeng2410@shutcm.edu.cn.
Lei ChenSurgical Department I (Urology Department), LONGHUA Hospital Shanghai University of Traditional Chinese Medicine, Xuhui District, No. 725 Wanping Road South, Shanghai, 200032, China. chenlei2114@shutcm.edu.cn.
Dan WangSurgical Department I (Urology Department), LONGHUA Hospital Shanghai University of Traditional Chinese Medicine, Xuhui District, No. 725 Wanping Road South, Shanghai, 200032, China. wangdan02282@shutcm.edu.cn.

Funding

General Program of National Natural Science Foundation of China 82174199Shanghai University of Traditional Chinese Medicine Industry Development Center Medical and Nursing Integrated Science and Technology Innovation Project 602069Dthe third batch of young Chinese name training program of LongHua Hospital Shanghai University of Traditional Chinese Medicine RC-2017-01-14
6 · The paper itself

Abstract

Paclitaxel resistance of castration-resistant prostate cancer (CRPC) remains a substantial challenge in clinical oncology. Our investigation aimed to explore the potential of stachydrine hydrochloride in addressing paclitaxel resistance within CRPC. Parental prostate cancer cells, PC3 and DU145, and the corresponding paclitaxel-resistant counterparts, PC3-TxR and DU145-TxR, were subjected to indicated concentrations to determine the IC50 of paclitaxel and stachydrine hydrochloride. Cell viability and proliferation were evaluated by MTT and colony formation assays. Stachydrine hydrochloride-mediated apoptosis, senescence, and ferroptosis were detected using Western blot, SA-β-gal staining, and QuantiChrom iron assay. We found a pronounced reduction in paclitaxel resistance in both PC3-TxR and DU145-TxR cells following exposure to stachydrine hydrochloride. The considerable decrease in paclitaxel's IC50 values in these cells highlights the potential of stachydrine hydrochloride in sensitizing CRPC cells to paclitaxel-based therapies. Mechanistically, stachydrine hydrochloride treatment significantly upregulated the expression of estrogen receptor beta (ERβ) and promoted cell apoptosis, senescence, and ferroptosis pathways in CRPC. Our study provides promising insights into the potential of stachydrine hydrochloride as a novel therapeutic adjunct in overcoming paclitaxel resistance in CRPC.

Indexed as

BenzophenanthridinesCellular SenescenceFerroptosisProstatic Neoplasms, Castration-ResistantApoptosisCell Line, TumorCell ProliferationCell SurvivalDrug Resistance, NeoplasmEstrogen Receptor betaHumansMalePaclitaxelProlineBenzophenanthridinesESR2 protein, humanEstrogen Receptor betaPaclitaxelProlinestachydrineApoptosisCastration-resistant prostate cancerFerroptosisSenescenceStachydrine hydrochloride

Identifiers

PMID40266302

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.